Your browser is no longer supported. Please, upgrade your browser.
Settings
ALKS Alkermes plc daily Stock Chart
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-0.76 Insider Own0.70% Shs Outstand155.33M Perf Week5.01%
Market Cap5.30B Forward P/E61.07 EPS next Y0.56 Insider Trans-1.34% Shs Float153.98M Perf Month7.29%
Income-117.90M PEG- EPS next Q-0.05 Inst Own- Short Float3.09% Perf Quarter-19.33%
Sales1.05B P/S5.03 EPS this Y35.30% Inst Trans-0.14% Short Ratio4.62 Perf Half Y-24.17%
Book/sh7.41 P/B4.61 EPS next Y161.21% ROA-7.90% Target Price42.69 Perf Year-40.07%
Cash/sh3.01 P/C11.36 EPS next 5Y64.99% ROE-11.90% 52W Range27.54 - 71.22 Perf YTD15.69%
Dividend- P/FCF1060.58 EPS past 5Y-47.10% ROI-9.50% 52W High-52.06% Beta1.86
Dividend %- Quick Ratio2.60 Sales past 5Y9.40% Gross Margin84.30% 52W Low23.97% ATR1.26
Employees2000 Current Ratio2.90 Sales Q/Q14.40% Oper. Margin-8.90% RSI (14)62.40 Volatility3.08% 4.00%
OptionableYes Debt/Eq0.24 EPS Q/Q6.10% Profit Margin-13.20% Rel Volume1.03 Prev Close33.82
ShortableYes LT Debt/Eq0.24 EarningsFeb 13 BMO Payout- Avg Volume1.03M Price34.14
Recom2.90 SMA2011.62% SMA502.44% SMA200-17.42% Volume1,060,725 Change0.95%
Dec-19-18Downgrade Goldman Neutral → Sell
Dec-14-18Initiated Wolfe Research Underperform
Dec-13-18Downgrade Credit Suisse Outperform → Underperform
Nov-05-18Initiated Piper Jaffray Neutral $40
Aug-07-18Initiated Stifel Hold $15 → $45
Jun-21-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jun-06-18Initiated B. Riley FBR, Inc. Buy $60
May-16-18Upgrade Citigroup Neutral → Buy
May-11-18Initiated BofA/Merrill Buy $56
Apr-02-18Downgrade Evercore ISI Outperform → In-line
Feb-22-18Downgrade Jefferies Buy → Hold
Oct-16-17Downgrade Barclays Overweight → Equal Weight $66 → $50
Jun-13-17Downgrade Leerink Partners Outperform → Mkt Perform
Oct-21-16Upgrade JP Morgan Neutral → Overweight
Oct-21-16Reiterated Leerink Partners Outperform $57 → $70
Oct-21-16Reiterated Jefferies Buy $62 → $70
Oct-04-16Resumed Leerink Partners Outperform $57
Jan-21-16Reiterated Leerink Partners Outperform $84 → $58
Jan-21-16Downgrade Morgan Stanley Overweight → Underweight
Jan-21-16Downgrade JP Morgan Overweight → Neutral
Jan-21-19 01:42PM  SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:00PM  SHAREHOLDER ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline: February 25, 2019 GlobeNewswire
10:51AM  ALKS DEADLINE: Rosen Law Firm Reminds Alkermes Public Limited Company Investors of Important February 25 Deadline in First-Filed Securities Class Action Lawsuit ALKS GlobeNewswire
Jan-18-19 07:57PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc ALKS GlobeNewswire
01:40PM  SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS ACCESSWIRE
12:52PM  SHAREHOLDER ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline: February 25, 2019 ACCESSWIRE
12:29PM  INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jan-16-19 07:50PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc ALKS ACCESSWIRE
02:10PM  IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:52PM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline: February 25, 2019 ACCESSWIRE
07:00AM  Alkermes Announces Recipients of 1st Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program PR Newswire
Jan-15-19 04:25PM  ALKS ALERT: Rosen Law Firm Files First Securities Class Action Lawsuit Against Alkermes Public Limited Company; Reminds Investors with $100K in Losses of Important Deadline ALKS GlobeNewswire
02:49PM  CLASS ACTION UPDATE for DXC and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Jan-14-19 07:04PM  INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
05:04PM  SHAREHOLDER ALERT: DNKEY ATUS DXC ALKS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
04:57PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm GlobeNewswire
02:45PM  February 25th Alkermes Shareholder Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against Alkermes plc ALKS GlobeNewswire
01:00PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline: February 25, 2019 GlobeNewswire
Jan-13-19 10:00AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of YRCW, YRIV and ALKS GlobeNewswire
08:55AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc - ALKS ACCESSWIRE
Jan-11-19 07:51PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc ALKS GlobeNewswire
05:25PM  IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:06PM  SHAREHOLDER ALERT: YRCW AGN ALKS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
09:50AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) & Lead Plaintiff Deadline: February 25, 2019 ACCESSWIRE
09:00AM  CLASS ACTION UPDATE for YRCW and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Jan-10-19 04:04PM  SHAREHOLDER ALERT: Berger Montague Announces Investigation of Alkermes, plc (NASDAQ: ALKS) (CUSIP: G01767105) PR Newswire
03:58PM  ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes plc To Contact The Firm ACCESSWIRE
03:10PM  INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:54PM  CLASS ACTION UPDATE for YRCW and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:49AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline: February 25, 2019 ACCESSWIRE
Jan-09-19 12:18PM  FEBRUARY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
10:39AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of WBT, DXC and ALKS GlobeNewswire
09:48AM  ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes plc To Contact The Firm Business Wire
09:31AM  Hagens Berman Notifies Alkermes Public Limited Company (NASDAQ: ALKS) Investors of Securities Fraud Class Action and February 25, 2019 Lead Plaintiff Deadline GlobeNewswire
09:30AM  CBM or ALKS: Which Is the Better Value Stock Right Now? Zacks
Jan-08-19 07:29PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc - ALKS PR Newswire
12:50PM  INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
12:18PM  ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Alkermes plc to Contact the Firm Business Wire
12:08PM  Robbins Arroyo LLP: Alkermes Public Limited Company (ALKS) Misled Shareholders According to a Recently Filed Class Action Business Wire
11:00AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline: February 25, 2019 GlobeNewswire
10:36AM  Investor Alert: Kaplan Fox Announces Investigation Of Alkermes plc PR Newswire
10:08AM  SHAREHOLDER ALERT: YRCW YRIV ALKS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Jan-07-19 09:06PM  CLASS ACTION UPDATE for PRGO and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
04:49PM  Alkermes plc, Inc. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Alkermes plc, Inc. GlobeNewswire
01:49PM  ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes plc To Contact The Firm PR Newswire
06:53AM  Tackling the opioid epidemic in America Fox Business Videos
Jan-04-19 06:13PM  Biogen Begins Improved Dosing Regimen on Tysabri in Phase III Zacks +5.63%
12:46PM  IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
09:04AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline: February 25, 2019 ACCESSWIRE
Jan-03-19 04:53PM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
Jan-02-19 04:00PM  Alkermes' Corporate Presentation to be Webcast at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire
09:04AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline: February 25, 2019 ACCESSWIRE
Dec-31-18 10:00AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline: February 25, 2019 GlobeNewswire
07:51AM  4 of the Fastest Growing Biotech Stocks in 2019 Motley Fool
07:00AM  Alkermes Class Action Lawsuit: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against Alkermes plc  ALKS GlobeNewswire
Dec-28-18 10:40AM  Alkermes Class Action Lawsuit: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Alkermes plc - ALKS PR Newswire
10:15AM  SINGLE TICKER NOTICE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS ACCESSWIRE
Dec-27-18 09:07PM  EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company ALKS Business Wire
Dec-24-18 02:30PM  SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
10:30AM  ALKS LOSS NOTICE: Rosen Law Firm Announces Investigation of Securities Claims Against Alkermes plc ALKS GlobeNewswire
Dec-19-18 09:29AM  Alkermes Catches A 'Sell' Downgrade On Depression Therapy, M&A Prospects Benzinga -6.07%
04:28AM  Do Hedge Funds Love Alkermes Plc (ALKS)? Insider Monkey
Dec-18-18 09:47AM  Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug Zacks
Dec-17-18 07:30AM  Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis GlobeNewswire
Dec-14-18 11:49AM  Need To Know: Alkermes plc (NASDAQ:ALKS) Insiders Have Been Selling Shares Simply Wall St.
Dec-12-18 01:47PM  ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Dec-10-18 07:40AM  New Research Coverage Highlights Tractor Supply, Shaw Communications, Alkermes plc, Jacobs Engineering Group, Eastman Chemical, and Varian Medical Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
05:00AM  Alkermes- A New Tool in Treating Schizophrenia MoneyShow
Dec-04-18 02:31PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Nov-29-18 10:49AM  Alkermes schizophrenia drug keeps weight gain side effect in check Reuters
09:17AM  Alkermes touts 'positive' schizophrenia drug data, but investors not impressed American City Business Journals
07:53AM  Alkermes reports positive results in trial of schizophrenia treatment that reduces weight gain MarketWatch
07:08AM  Alkermes schizophrenia treatment meets main goals in late-stage study Reuters
07:01AM  Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia PR Newswire
Nov-22-18 09:30AM  Alkermes (ALKS) Down 14.2% Since Last Earnings Report: Can It Rebound? Zacks
Nov-19-18 02:32PM  INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Nov-16-18 11:32AM  INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
09:21AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alkermes plc, Inc. (ALKS) ACCESSWIRE
Nov-15-18 10:52PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
04:58PM  Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation of Alkermes plc - ALKS GlobeNewswire
04:13PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Alkermes plc ALKS Business Wire
Nov-12-18 01:00AM  Just How Bad Is Alkermes' Depression Drug Setback? Motley Fool -7.88%
Nov-09-18 11:09AM  Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation Of Alkermes plc - ALKS PR Newswire
07:32AM  The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall Benzinga
Nov-08-18 04:55PM  Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit From M&A Motley Fool
Nov-06-18 04:01PM  Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences PR Newswire
08:01AM  Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting PR Newswire
Nov-02-18 03:32PM  Is Alkermes plc (NASDAQ:ALKS) Overpaying Its CEO? Simply Wall St. -7.57%
10:16AM  FDA Committees' Unfavorable Ruling Depresses Alkermes Shares Benzinga
08:01AM  The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug Benzinga
Nov-01-18 06:57PM  Alkermes stock falls after FDA committee votes against depression drug MarketWatch
06:25PM  Alkermes' depression treatment fails to get FDA panel backing Reuters
06:24PM  Alkermes Reports on Outcome of FDA Advisory Committee Meeting on ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder PR Newswire
05:15PM  Alkermes depression drug in peril after FDA advisory vote American City Business Journals
05:05PM  FDA panel votes against Alkermes' depression treatment Reuters
02:03PM  Alkermes depression drug facing FDA panel, here's what to... CNBC Videos
09:05AM  Alkermes stock halted as FDA committee considers depression drug MarketWatch
07:00AM  Trading in Alkermes Ordinary Shares Halted Today PR Newswire
Oct-31-18 08:45AM  New Research: Key Drivers of Growth for Alkermes plc, PulteGroup, Las Vegas Sands, Barrick Gold, Avangrid, and Fomento Economico Mexicano S.A.B. de C.V Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Oct-30-18 09:01AM  Alkermes stock drops 6.5% after FDA briefing documents raise questions about depression drug MarketWatch
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes. It is also developing Aripiprazole Lauroxil NanoCrystal Dispersion; ALKS 5461 for the treatment of depressive disorder; ALKS 3831 to treat schizophrenia; BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; and ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; development and license agreement with AstraZeneca plc; and license and collaboration agreement with Biogen MA Inc. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MITCHELL PAUL JDirectorJan 04Option Exercise8.981,0008,9801,000Jan 04 06:01 PM
MITCHELL PAUL JDirectorJan 04Sale30.001,00030,0000Jan 04 06:01 PM
ANSTICE DAVID WDirectorDec 12Option Exercise8.9820,000179,60071,213Dec 13 06:30 PM
ANSTICE DAVID WDirectorDec 12Sale35.598,787312,71066,213Dec 13 06:30 PM
MITCHELL PAUL JDirectorDec 03Option Exercise8.981,0008,9801,000Dec 06 06:10 PM
MITCHELL PAUL JDirectorDec 03Sale36.451,00036,4500Dec 06 06:10 PM
MITCHELL PAUL JDirectorNov 02Option Exercise8.981,0008,9801,000Nov 02 05:22 PM
MITCHELL PAUL JDirectorNov 02Sale37.511,00037,5100Nov 02 05:22 PM
MITCHELL PAUL JDirectorOct 01Option Exercise8.981,0008,9801,000Oct 02 07:52 PM
MITCHELL PAUL JDirectorOct 01Sale42.421,00042,4200Oct 02 07:52 PM
MITCHELL PAUL JDirectorSep 04Option Exercise8.981,0008,9801,000Sep 05 04:22 PM
MITCHELL PAUL JDirectorSep 04Sale44.581,00044,5800Sep 05 04:22 PM
MITCHELL PAUL JDirectorAug 01Option Exercise8.981,0008,9801,000Aug 03 04:26 PM
MITCHELL PAUL JDirectorAug 01Sale43.681,00043,6800Aug 03 04:26 PM
BLOOM FLOYD EDirectorJul 16Sale43.9520,000879,024127,923Jul 18 07:51 PM
MITCHELL PAUL JDirectorJul 03Option Exercise8.981,0008,9801,000Jul 03 05:08 PM
MITCHELL PAUL JDirectorJul 03Sale41.861,00041,8600Jul 03 05:08 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSJun 12Sale50.0016,842842,17937,234Jun 13 08:26 PM
Hopkinson Craig C.SVP, Med Dev/Med Affairs, CMOJun 07Option Exercise0.001,25001,250Jun 08 05:31 PM
MITCHELL PAUL JDirectorJun 01Option Exercise8.981,0008,9801,000Jun 04 05:18 PM
MITCHELL PAUL JDirectorJun 01Sale47.341,00047,3400Jun 04 05:18 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 24Option Exercise12.2920,000245,800192,644May 24 05:24 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 24Sale45.2220,000904,424172,644May 24 05:24 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 22Option Exercise12.2920,000245,800686,352May 24 05:18 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 22Sale45.4620,000909,163666,352May 24 05:18 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.May 18Option Exercise12.292753,38036,638May 21 06:25 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 17Option Exercise12.2920,000245,800192,644May 17 07:01 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 17Sale46.1420,000922,846172,644May 17 07:01 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 15Option Exercise12.2950,000614,500716,352May 17 05:21 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 15Sale46.3850,0002,319,100666,352May 17 05:21 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 08Option Exercise12.2950,000614,500716,352May 10 06:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 08Sale44.3250,0002,215,775666,352May 10 06:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 01Option Exercise12.2950,000614,500716,352May 03 05:13 PM
MITCHELL PAUL JDirectorMay 01Option Exercise8.981,0008,9801,000May 03 05:34 PM
MITCHELL PAUL JDirectorMay 01Sale44.321,00044,3200May 03 05:34 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 01Sale44.0250,0002,201,167666,352May 03 05:13 PM
MITCHELL PAUL JDirectorApr 02Option Exercise8.981,0008,9801,000Apr 04 06:41 PM
MITCHELL PAUL JDirectorApr 02Sale46.751,00046,7500Apr 04 06:41 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncMar 03Option Exercise0.002,813052,316Mar 05 06:33 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 03Option Exercise0.0013,0000672,131Mar 05 06:27 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 03Option Exercise0.002,8130173,598Mar 05 06:16 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 03Option Exercise0.001,250036,732Mar 05 06:09 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 03Option Exercise0.002,813085,369Mar 05 06:02 PM
Cooke ShanePresident, Alkermes plcMar 03Option Exercise0.005,250087,602Mar 05 05:55 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO/CRO Alks Inc;Mar 03Option Exercise0.003,500041,756Mar 05 05:46 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Mar 03Option Exercise0.001,250022,264Mar 05 05:35 PM
MITCHELL PAUL JDirectorMar 01Option Exercise11.441,00011,4409,000Mar 05 05:05 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncMar 01Option Exercise0.005,250051,837Mar 05 06:33 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 01Option Exercise0.0017,5000666,910Mar 05 06:27 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 01Option Exercise0.004,5000172,111Mar 05 06:16 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 01Option Exercise0.002,250036,145Mar 05 06:09 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 01Option Exercise0.004,500083,882Mar 05 06:02 PM
Cooke ShanePresident, Alkermes plcMar 01Option Exercise0.007,000085,992Mar 05 05:55 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO/CRO Alks Inc;Mar 01Option Exercise0.005,750040,463Mar 05 05:46 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Mar 01Option Exercise0.002,250021,677Mar 05 05:35 PM
MITCHELL PAUL JDirectorMar 01Sale57.041,00057,0408,000Mar 05 05:05 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncFeb 26Option Exercise0.002,625047,754Feb 28 06:46 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 26Option Exercise0.0010,0000653,855Feb 28 06:42 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 26Option Exercise0.002,6250168,385Feb 28 06:37 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 26Option Exercise0.001,100034,219Feb 28 06:30 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 26Option Exercise0.002,625080,156Feb 28 06:18 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 26Option Exercise0.001,100019,751Feb 28 05:49 PM
Cooke ShanePresident, Alkermes plcFeb 26Option Exercise0.004,425081,293Feb 28 05:54 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO/CRO Alks Inc;Feb 26Option Exercise0.003,750035,818Feb 28 05:40 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO/CRO Alks Inc;Feb 20Option Exercise17.9917,242310,18432,068Feb 21 05:37 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 17Option Exercise0.008,7500646,436Feb 21 06:07 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncFeb 17Option Exercise0.003,000047,013Feb 21 06:10 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 17Option Exercise0.003,0000166,693Feb 21 06:01 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 17Option Exercise0.003,0000147,039Feb 21 05:55 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 17Option Exercise0.002,500033,907Feb 21 06:00 PM
Cooke ShanePresident, Alkermes plcFeb 17Option Exercise0.004,500079,208Feb 21 05:51 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 17Option Exercise0.002,500019,443Feb 21 05:44 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO/CRO Alks Inc;Feb 17Option Exercise0.003,750015,974Feb 21 05:37 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncFeb 16Option Exercise17.3010,880188,22454,893Feb 21 06:10 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncFeb 16Sale70.5010,880767,09244,013Feb 21 06:10 PM
Cooke ShanePresident, Alkermes plcFeb 02Option Exercise16.5572,7931,204,724147,501Feb 02 06:07 PM
Cooke ShanePresident, Alkermes plcFeb 02Sale60.5572,7934,407,67974,708Feb 02 06:07 PM
MITCHELL PAUL JDirectorFeb 01Option Exercise11.441,00011,4409,000Feb 02 06:04 PM
MITCHELL PAUL JDirectorFeb 01Sale56.771,00056,7708,000Feb 02 06:04 PM
Cooke ShanePresident, Alkermes plcJan 29Option Exercise16.553,30054,61578,008Jan 29 09:55 PM
Cooke ShanePresident, Alkermes plcJan 29Sale60.003,300198,00074,708Jan 29 09:55 PM
Cooke ShanePresident, Alkermes plcJan 26Option Exercise16.551,70028,13576,408Jan 29 09:55 PM
Cooke ShanePresident, Alkermes plcJan 26Sale60.021,700102,02874,708Jan 29 09:55 PM